FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2790593368> ?p ?o ?g. }

• W2790593368 endingPage "496" @default.
• W2790593368 startingPage "490" @default.
• W2790593368 abstract "FOLFOXIRI is now regarded as the chemotherapy regimen that offers the best platform for the treatment of colorectal cancer. However, the safety and efficacy of FOLFOXIRI + panitumumab has not been demonstrated. We conducted a phase I study to determine the recommended dose of FOLFOXIRI + panitumumab as first-line treatment for RAS wild-type metastatic colorectal cancer (mCRC).Patients received combination therapy consisting of panitumumab (6 mg/kg on day 1) + FOLFOXIRI [irinotecan (CPT-11), oxaliplatin (L-OHP) 85 mg/m2, and folinate (LV) 200 mg/m2] on day 1, followed by fluorouracil (5-FU) 3200 mg/m2 infused as a 46-h continuous infusion starting on day 1) repeated every 2 weeks as first-line treatment of RAS wild-type mCRC patients. A decrease in CPT-11 dose was planned (started at level 1: CPT-11 165 mg/m2).Seven patients were enrolled, and six were assessed for safety and efficacy. Maximum tolerated dose was not reached at level 1; all patients were treated at these levels. The common Grade 3 or 4 relevant toxicities were diarrhea (50%), hypokalemia (33%) and stomatitis (33%). No treatment-related deaths occurred. Of the six patients assessed four had partial response and the two others had stable disease; hence, the response rate was 66.7% (95% confidence interval 28.9-100%) and the disease control rate was 100%. Time to protocol treatment failure was 7.2 (1.4-7.3) months.The FOLFOXIRI + panitumumab chemotherapy regimen was well tolerated by our patients with mCRC and showed promising anti-tumor activity. The recommended phase II dose was determined to be the same as the standard doses of this regimen used worldwide." @default.
• W2790593368 created "2018-03-29" @default.
• W2790593368 creator A5001002762 @default.
• W2790593368 creator A5011507410 @default.
• W2790593368 creator A5013099735 @default.
• W2790593368 creator A5015382936 @default.
• W2790593368 creator A5034173949 @default.
• W2790593368 creator A5045819149 @default.
• W2790593368 creator A5054365571 @default.
• W2790593368 creator A5062868734 @default.
• W2790593368 creator A5068132612 @default.
• W2790593368 creator A5076136934 @default.
• W2790593368 creator A5087398756 @default.
• W2790593368 creator A5089426897 @default.
• W2790593368 creator A5091876480 @default.
• W2790593368 date "2018-02-20" @default.
• W2790593368 modified "2023-09-23" @default.
• W2790593368 title "Phase I study of primary treatment with 5-FU, oxaliplatin, irinotecan, levofolinate, and panitumumab combination chemotherapy in patients with advanced/recurrent colorectal cancer involving the wild-type RAS gene: the JACCRO CC-14 study" @default.
• W2790593368 cites W1783674673 @default.
• W2790593368 cites W1966201413 @default.
• W2790593368 cites W1993780950 @default.
• W2790593368 cites W1995854801 @default.
• W2790593368 cites W2046116942 @default.
• W2790593368 cites W2053230335 @default.
• W2790593368 cites W2098354753 @default.
• W2790593368 cites W2106845199 @default.
• W2790593368 cites W2142650716 @default.
• W2790593368 cites W2149628418 @default.
• W2790593368 doi "https://doi.org/10.1007/s10147-017-1228-5" @default.
• W2790593368 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5951897" @default.
• W2790593368 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29464396" @default.
• W2790593368 hasPublicationYear "2018" @default.
• W2790593368 type Work @default.
• W2790593368 sameAs 2790593368 @default.
• W2790593368 citedByCount "7" @default.
• W2790593368 countsByYear W27905933682019 @default.
• W2790593368 countsByYear W27905933682021 @default.
• W2790593368 countsByYear W27905933682022 @default.
• W2790593368 crossrefType "journal-article" @default.
• W2790593368 hasAuthorship W2790593368A5001002762 @default.
• W2790593368 hasAuthorship W2790593368A5011507410 @default.
• W2790593368 hasAuthorship W2790593368A5013099735 @default.
• W2790593368 hasAuthorship W2790593368A5015382936 @default.
• W2790593368 hasAuthorship W2790593368A5034173949 @default.
• W2790593368 hasAuthorship W2790593368A5045819149 @default.
• W2790593368 hasAuthorship W2790593368A5054365571 @default.
• W2790593368 hasAuthorship W2790593368A5062868734 @default.
• W2790593368 hasAuthorship W2790593368A5068132612 @default.
• W2790593368 hasAuthorship W2790593368A5076136934 @default.
• W2790593368 hasAuthorship W2790593368A5087398756 @default.
• W2790593368 hasAuthorship W2790593368A5089426897 @default.
• W2790593368 hasAuthorship W2790593368A5091876480 @default.
• W2790593368 hasBestOaLocation W27905933682 @default.
• W2790593368 hasConcept C121608353 @default.
• W2790593368 hasConcept C126322002 @default.
• W2790593368 hasConcept C143998085 @default.
• W2790593368 hasConcept C2776694085 @default.
• W2790593368 hasConcept C2776705615 @default.
• W2790593368 hasConcept C2778332735 @default.
• W2790593368 hasConcept C2779984678 @default.
• W2790593368 hasConcept C2780259306 @default.
• W2790593368 hasConcept C2780962732 @default.
• W2790593368 hasConcept C2781187634 @default.
• W2790593368 hasConcept C2781413609 @default.
• W2790593368 hasConcept C31760486 @default.
• W2790593368 hasConcept C526805850 @default.
• W2790593368 hasConcept C71924100 @default.
• W2790593368 hasConcept C90924648 @default.
• W2790593368 hasConceptScore W2790593368C121608353 @default.
• W2790593368 hasConceptScore W2790593368C126322002 @default.
• W2790593368 hasConceptScore W2790593368C143998085 @default.
• W2790593368 hasConceptScore W2790593368C2776694085 @default.
• W2790593368 hasConceptScore W2790593368C2776705615 @default.
• W2790593368 hasConceptScore W2790593368C2778332735 @default.
• W2790593368 hasConceptScore W2790593368C2779984678 @default.
• W2790593368 hasConceptScore W2790593368C2780259306 @default.
• W2790593368 hasConceptScore W2790593368C2780962732 @default.
• W2790593368 hasConceptScore W2790593368C2781187634 @default.
• W2790593368 hasConceptScore W2790593368C2781413609 @default.
• W2790593368 hasConceptScore W2790593368C31760486 @default.
• W2790593368 hasConceptScore W2790593368C526805850 @default.
• W2790593368 hasConceptScore W2790593368C71924100 @default.
• W2790593368 hasConceptScore W2790593368C90924648 @default.
• W2790593368 hasIssue "3" @default.
• W2790593368 hasLocation W27905933681 @default.
• W2790593368 hasLocation W27905933682 @default.
• W2790593368 hasLocation W27905933683 @default.
• W2790593368 hasLocation W27905933684 @default.
• W2790593368 hasOpenAccess W2790593368 @default.
• W2790593368 hasPrimaryLocation W27905933681 @default.
• W2790593368 hasRelatedWork W155879507 @default.
• W2790593368 hasRelatedWork W1792988773 @default.
• W2790593368 hasRelatedWork W1966121666 @default.
• W2790593368 hasRelatedWork W2010928484 @default.
• W2790593368 hasRelatedWork W2132754339 @default.
• W2790593368 hasRelatedWork W2147138752 @default.
• W2790593368 hasRelatedWork W2545945608 @default.
• W2790593368 hasRelatedWork W2617055067 @default.

• next